Announcements

Motif Selected to Present at World’s Largest Biotech Event

By May 12, 2015June 14th, 2016No Comments

Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria, announced today that the Company has been selected to present at the 2015 BIO International Convention, the leading global event for the Biotechnology sector.

BIO International is the world’s largest biotech meeting, regularly attracting 15,000 of the world’s most powerful biotechnology and pharmaceutical players from 65 countries, offering unparalleled business partnering, education and networking. The convention is to be held in the Pennsylvania Convention Centre, Philadelphia, Pennsylvania, USA, on 15-18 June 2015.

Enquiries

Motif Bio plc

Graham Lumsden, Chief Executive Officer
Robert Bertoldi, Chief Financial Officer
info@motifbio.com

Plumtree Capital Limited (Financial Adviser)

Stephen Austin
+44 (0) 207 183 5860

Zeus Capital Limited (Nominated Advisor and Broker)

Phil Walker / Dan Bate
Dominic Wilson
+44 (0) 20 3829 5000

Northland Capital Partners Limited (Broker)

Gerry Beaney
David Hignell
John Howes
Mark Treharne
+44 (0) 207 382 1100

Yellow Jersey (London IR)

Dominic Barretto
Philip Ranger
Fiona Walker
+44 (0) 7768 537 739

MC Services (European PR)

Dominic Barretto
Philip Ranger
Fiona Walker
+44 (0) 7768 537 739

Notes to Editors

Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolate reductase inhibitor (DHFRi).

Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.